Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology

Table of Contents

1 Executive Summary

2 Table of Contents

• 2.1 List of Boxes
• 2.2 List of Figures
• 2.3 List of Tables

3 Methodology

4 Introduction to Apoptosis in Oncology

5 Apoptosis Competitive Landscape in Oncology

• 5.1 Countries & Players: Who are In the Lead?
• 5.1.1 Top 10 Players Dominate The Developmental Pipeline
• 5.2 Deals & Alliances in Apoptosis Drug Development
  • 5.2.1 Review of Deals and Alliances Initiated in 2006
  • 5.2.2 Review of Deals and Alliances Initiated in 2005
  • 5.2.3 Review of Deals and Alliances Initiated in 2004
  • 5.2.4 Review of Deals and Alliances Initiated in 2003
  • 5.2.5 Review of Deals and Alliances Initiated in 2002
  • 5.2.6 Review of Deals and Alliances Initiated in 2001

6 Approved Apoptopic Cancer Drugs: Performance

7 Target Analysis in Apoptosis

• 7.1 Targets of Late Stage Apoptopic Drugs in Development
  • 7.1.1 B-cell CLL/lymphoma 2
  • 7.1.2 Caspase 3
  • 7.1.3 CD4 molecule
  • 7.1.4 Cytosolic ovarian carcinoma antigen 1
  • 7.1.5 Eukaryotic translation elongation factor 2
  • 7.1.6 Farnesyltransferase, CAAX box, alpha
  • 7.1.7 Fc fragment of IgE
  • 7.1.8 Histone deacetylase 1
  • 7.1.9 Histone deacetylase 2
  • 7.1.10 Interleukin 13 receptor, alpha 1
  • 7.1.11 Phosphodiesterase 2A, cGMP-stimulated
  • 7.1.12 Phosphodiesterase 5A, cGMP-specific
  • 7.1.13 Protein kinase C, beta 1
  • 7.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
  • 7.1.15 Topoisomerase (DNA) I
  • 7.1.16 Topoisomerase (DNA) II alpha
  • 7.1.17 Tubulin, beta polypeptide
  • 7.1.18 p53 protein
• 7.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
  • 7.2.1 Targets in Breast Cancer
  • 7.2.2 Targets in Leukemia
  • 7.2.3 Targets in Lung Cancer
  • 7.2.4 Targets in Lymphoma
  • 7.2.5 Targets in Prostate Cancer

8 Apoptopic Drugs in Development: By Major Indications

• 8.1 General Drug Developmental Overview
  • 8.1.1 Apoptopic Drugs in Phase III Clinical Development
  • 8.1.2 Failed Apoptopic Drugs in Oncology
• 8.2 Progress Analysis - Breast Cancer
  • 8.2.1 Phase I Clinical Development
  • 8.2.2 Phase II Clinical Development
  • 8.2.3 Phase III Clinical Development
• 8.3 Progress Analysis - Leukemia
  • 8.3.1 Phase I Clinical Development
  • 8.3.2 Phase II Clinical Development
  • 8.3.3 Phase III Clinical Development
• 8.4 Progress Analysis - Lung Cancer
  • 8.4.1 Phase I Clinical Development
  • 8.4.2 Phase II Clinical Development
  • 8.4.3 Phase III Clinical Development
• 8.5 Progress Analysis - Lymphoma
  • 8.5.1 Phase I Clinical Development
  • 8.5.2 Phase II Clinical Development
  • 8.5.3 Phase III Clinical Development
• 8.6 Progress Analysis - Prostate Cancer
  • 8.6.1 Phase I Clinical Development
  • 8.6.2 Phase II Clinical Development
  • 8.6.3 Phase III Clinical Development

9 Immunotherapy in Oncology

• 9.1 Vaccine Strategies: Challenges & Opportunities
• 9.2 Key Antibody Developmental Strategies

10 Competitive Landscape in Cancer Vaccines

• 10.1 Countries & Players: Who are In the Lead?
  • 10.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  • 10.1.2 Approved Cancer Vaccine Drugs: Performance
• 10.2 Deals & Alliances in Cancer Vaccines
  • 10.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  • 10.2.2 Deals in Prostate Cancer
  • 10.2.3 Deals in Breast Cancer
  • 10.2.4 Deals in Leukemia & Lymphoma
  • 10.2.5 Drug Delivery Deals in Cancer Vaccines
  • 10.2.6 Adjuvant Deals

11 Antibody Deals on the Rise

• 11.1 Antibody Deals in Phase III
  • 11.1.1 Deal Situation: MDX 010
  • 11.1.2 Deal Situation: WX G250
  • 11.1.3 Deal Situation: Zanolimumab
• 11.2 Antibody Deals in Phase II
  • 11.2.1 Deal Situation: Mapatumumab
  • 11.2.2 Deal Situation: GCR 3888
  • 11.2.3 Deal Situation: MDX 070
  • 11.2.4 Deal Situation: CDP 860
  • 11.2.5 Deal Situation: Tru-Scint OV
  • 11.2.6 Deal Situation: SC 1
  • 11.2.7 Deal Situation: PRO 70769
  • 11.2.8 Deal Situation: XR 303
  • 11.2.9 Deal Situation: HumaRAD-HN

12 Tumor Antigens

• 12.1 Tumor Antigens: General Comments
• 12.2 Antigen Discovery
  • 12.2.1 Classical Immunology Approach
  • 12.2.2 The Reverse Immunology Approach
  • 12.2.3 Company Platforms
• 12.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

13 Immunomodulators & Adjuvants in Cancer Vaccines

• 13.1 Overview
• 13.2 Cytokines
  • 13.2.1 Vaccines in Combination with Interleukin-2
  • 13.2.2 Tumor Necrosis Factor
  • 13.2.3 Interferons
• 13.3 Adjuvants
• 13.4 Other Immunomodulating Strategies
  • 13.4.1 An Immune Response Modifying Protein
  • 13.4.2 Immunostimulatory DNA
  • 13.4.3 Ex Vivo Stimulated Immune Cells
  • 13.4.4 Fusion Protein Gain Potent Immune Response
  • 13.4.5 Macrophage and Natural Killer Cells Activation
  • 13.4.6 Selective Suppression of the Immune System to An Antigen
  • 13.4.7 TAP Technology

14 Cancer Vaccine Delivery

• 14.1 Viral Delivery
  • 14.1.1 Introduction
  • 14.1.2 Viral Constructs Put into Use
• 14.2 Bacterias
• 14.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  • 14.3.1 Introduction
  • 14.3.2 Cell Therapy Strategies
• 14.4 Synthetic Delivery Systems & Strategies
  • 14.4.1 Introduction
  • 14.4.2 Biotransport™
  • 14.4.3 Biotype®vector
  • 14.4.4 DNAVax Gene Delivery System
  • 14.4.5 FusitAb™
  • 14.4.6 GeneDrug™
  • 14.4.7 Molecular Conjugates
  • 14.4.8 Naked DNA Delivery
  • 14.4.9 PVLP Technology
  • 14.4.10 Sphingosomal Drug Delivery Technology
  • 14.4.11 STEALTH
  • 14.4.12 Failed Liposomal Systems

15 New Approaches in Antibody Delivery and Design - The Next Generation

• 15.1 How to Make Them Smaller and Different?
• 15.2 Biomaterials in Sustained Delivery Applications
  • 15.2.1 Implants
• 15.3 Gene delivery - the Future?
  • 15.3.1 Delivery Vehicles for DNA
  • 15.3.2 Gene Delivery in Commercialization

16 Cancer Vaccines in Development: By Major Indications

• 16.1 General Oncology Overview
• 16.2 Progress Analysis - Melanoma
• 16.3 Progress Analysis - Breast Cancer
• 16.4 Progress Analysis - Prostate Cancer
• 16.5 Progress Analysis - Lung Cancer
• 16.6 Progress Analysis - Colorectal Cancer
• 16.7 Progress Analysis - Cervical Cancer

17 Antibodies in Clinical Development

• 17.1.1 Prostate Cancer Therapeutics
• 17.1.2 Breast Cancer Therapeutics
• 17.1.3 Colorectal Cancer Therapeutics
• 17.1.4 Melanoma Therapeutics
• 17.1.5 Hematological Cancers Therapeutics
• 17.2 Antibodies in Phase III Clinical Development
  • 17.2.1 Progress Analysis: IGN 101
  • 17.2.2 Progress Analysis: MDX 010
  • 17.2.3 Progress Analysis: ONYVAX 105
  • 17.2.4 Progress Analysis: Ovarex
  • 17.2.5 Progress Analysis: Panitumumab
  • 17.2.6 Progress Analysis: RENCAREX
  • 17.2.7 Progress Analysis: Nimotuzumab
  • 17.2.8 Progress Analysis: TransMID
  • 17.2.9 Progress Analysis: Lintuzumab
  • 17.2.10 Progress Analysis: Zanolimumab
• 17.3 Antibodies in Phase II Clinical Development
  • 17.3.1 Progress Analysis: ABT-510
  • 17.3.2 Progress Analysis: BB 10901
  • 17.3.3 Progress Analysis: CP 675206
  • 17.3.4 Progress Analysis: CNTO-328
  • 17.3.5 Progress Analysis: Ecromeximab
  • 17.3.6 Progress Analysis: EMD 273063
  • 17.3.7 Progress Analysis: WX-G250RIT
  • 17.3.8 Progress Analysis: HGS-ETR1
  • 17.3.9 Progress Analysis: HuMax-CD20
  • 17.3.10 Progress Analysis: HuMax-EGFr
  • 17.3.11 Progress Analysis: Galiximab
  • 17.3.12 Progress Analysis: PROXINIUM
  • 17.3.13 Progress Analysis: RAV12
  • 17.3.14 Progress Analysis: SGN-15
  • 17.3.15 Progress Analysis: SGN-30
  • 17.3.16 Progression Analysis: VEGF-Trap
  • 17.3.17 Progress Analysis: MEDI 522
  • 17.3.18 Progress Analysis: Volociximab

18 Disclaimer

19 Company Index

20 Drug Index

List of Boxes

• Box 1: Business & Market - PXD-101
• Box 2: Business & Market - MG-98
• Box 3: Business & Market - VX-680
• Box 4: Business & Market - Ceflatonin
• Box 5: Business & Market - Oblimersen sodium
• Box 6: Business & Market - motexafin gadolinium
• Box 7: Business & Market - 1D09C3
• Box 8: Business & Market - PCK-3145
• Box 9: Business & Market - ME-2
• Box 10: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
• Box 11: M-VAX - Business & Market Bakground
• Box 12: Gardasil: Business & Market Background
• Box 13: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
• Box 14: TNF in Cancer Treatments
• Box 15: Marrion' s Drug Delivery Technology
• Box 16: Quick Facts - IGN 101
• Box 17: Quick Facts - MDX 010
• Box 18: Quick Facts - ONYVAX 105
• Box 19: Quick Facts - Ovarex
• Box 20: Quick Facts - Panitumumab
• Box 21: Quick Facts - RENCARNEX
• Box 22: Quick Facts - Nimotuzumab
• Box 23: Quick Facts - RENCARNEX
• Box 24: Quick Facts - Lintuzumab
• Box 25: Quick Facts - Zanolimumab
• Box 26: Quick Facts - ABT-510
• Box 27: Quick Facts - BB 10901
• Box 28: Quick Facts - CP-675206
• Box 29: Quick Facts - CNTO-328
• Box 30: Quick Facts - Ecromeximab
• Box 31: Quick Facts - EMD-273063
• Box 32: Quick Facts - WX-G250RIT
• Box 33: Quick Facts - HGS-ETR1
• Box 34: Quick Facts - HuMax-CD20
• Box 35: Quick Facts - HuMax-EGFr
• Box 36: Quick Facts - Galiximab
• Box 37: Quick Facts - PROXINIUM
• Box 38: Quick Facts - RAV12
• Box 39: Quick Facts -SGN-15
• Box 40: Quick Facts -SGN-30
• Box 41: Quick Facts - VEGF-Trap
• Box 42: Quick Facts - MEDI 522
• Box 43: Quick Facts - Volociximab

List of Figures

• Figure 1: Top 5 Countries in Apoptopic Cancer Research
• Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
• Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
• Figure 4: Distribution of ApoptopicTrials in Breast Cancer
• Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
• Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
• Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
• Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
• Figure 9: Top 10 Countries in Cancer Vaccine Research
• Figure 10: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
• Figure 11: 2003-2005 Deals & Alliances in Cancer Vaccine
• Figure 12: Distribution of Cancer Vaccine Trials in Melanoma
• Figure 13: Distribution of Cancer Vaccine Trials in Breast Cancer
• Figure 14: Distribution of Cancer Vaccine Trials in Prostate Cancer
• Figure 15: Distribution of Cancer Vaccine Trials in Lung Cancer
• Figure 16: Distribution of Cancer Vaccine Trials in Colorectal Cancer
• Figure 17: Distribution of Cancer Vaccine Trials in Cervical Cancer

List of Tables

• Table 1: Top 10' s Apoptopic Pipeline Drugs
• Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
• Table 3: Companies with Apoptopic Cancer Drugs on the Market
• Table 4: List of 120 Known Targets in Apoptosis Drug Development
• Table 5: Known Targets of Late Stage Apoptopic Drugs Development
• Table 6: Drugs with Bcl-2 as a Target
• Table 7: Drugs with Casp-3 as a Target
• Table 8: Drugs with CD4 molecule as a Target
• Table 9: Drugs with Cova-1 as a Target
• Table 10: Drugs with Eef-2 as a Target
• Table 11: Drugs with Fnta as a Target
• Table 12: Drugs with Fcer-2 as a Target
• Table 13: Drugs with Hdac-1 as a Target
• Table 14: Drugs with Hdac-2 as a Target
• Table 15: Drugs with IL13-RA1 as a Target
• Table 16: Drugs with Pde-2A as a Target
• Table 17: Drugs with Pde-5A as a Target
• Table 18: Drugs with Prkcb-1 as a Target
• Table 19: Drugs with Srd-5A1 as a Target
• Table 20: Drugs with Top-1 as a Target
• Table 21: Drugs with Top-2A as a Target
• Table 22: Drugs with Top-2A as a Target
• Table 23: Drugs with p53 protein as a Target
• Table 24: Breast Cancer Targets in Apoptopic Drug Development
• Table 25: Leukemia Targets in Apoptopic Drug Development
• Table 26: Lung Cancer Targets in Apoptopic Drug Development
• Table 27: Lymhoma Targets in Apoptopic Drug Development
• Table 28: Prostate Cancer Targets in Apoptopic Drug Development
• Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
• Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
• Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
• Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
• Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
• Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
• Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
• Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer
• Table 37: Summary of Strategies Enhancing Antibody Function
• Table 38: Companies with Cancer Vaccine Drugs on Market
• Table 39: Antigen Classification
• Table 40: Platforms Used to Improve Antigen Presentation
• Table 41: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
• Table 42: Adjuvants in Cancer Vaccines
• Table 43: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
• Table 44: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
• Table 45: Drug Delivery Companies with Cancer Focus
• Table 46: FDA Approved Polymer-based Drug Delivery Systems for Cancer
• Table 47 Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
• Table 48: Discountinued Phase I to Phase III Cancer Vaccine Drugs
• Table 49: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
• Table 50: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
• Table 51: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
• Table 52: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
• Table 53: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
• Table 54: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer
• Table 55: Antibody Therapeutics in Prostate Cancer
• Table 56: Antibody Therapeutics in Breast Cancer
• Table 57: Antibody Therapeutics in Colorectal Cancer
• Table 58: Antibody Therapeutics in Melanoma
• Table 59: Antibody Therapeutics in Hematological Cancer
• Table 60: MDX-010' s Collaborative History and Landscape